ERBB2 and breast cancer: In current clinical practice, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines recommend a dichotomous classification of HER2 status, HER2-positive (HER2 +) and HER2-negative (HER2-) BC, to instruct clinical treatment.